Venus Remedies Limited (VENUSREM) Financial History

Name: Venus Remedies Limited (VENUSREM) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Venus Remedies Limited (VENUSREM) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Panchkula, India with about 1,472 employees. Its market capitalization is roughly ₹21 billion. In the fiscal year ended 2026-03-31, VENUSREM reported ₹7.3B in revenue and ₹1.0B in net income.

Venus Remedies Limited engages in the pharmaceutical business in India, Latin America, Europe, the Middle East, Africa, Asia, and internationally. The company is involved in the research and development of solutions focusing on antimicrobial resistance, oncology, skin and wound care, and pain management.

Interactive charts & full statements →

VENUSREM Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹7.3B	₹6.5B	₹5.9B	₹5.5B	—
Gross Profit	₹3.2B	₹2.5B	₹2.2B	₹2.1B	—
Operating Income (EBIT)	₹1.1B	₹410M	₹332M	₹277M	—
Net Income	₹1.0B	₹453M	₹285M	₹266M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VENUSREM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹1.8B	₹2.6B	₹1.8B	₹1.9B	₹1.4B
Gross Profit	₹946M	₹1.4B	₹940M	₹854M	₹630M
Operating Income (EBIT)	₹274M	₹567M	₹310M	₹248M	₹92M
Net Income	₹230M	₹475M	₹256M	₹201M	₹96M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VENUSREM Free Cash Flow History

VENUSREM Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹8.5B	₹7.2B	₹6.3B	₹6.0B	—
Total Liabilities	₹1.9B	₹1.5B	₹1.4B	₹1.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VENUSREM viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

WINDLAS · Windlas Biotech Limited — ₹23 billion
FREDUN · Fredun Pharmaceuticals Limited — ₹22 billion
6887 · Sunshine Lake Pharma Co., Ltd. — HK$21 billion
2929 · Pharma Foods International Co., Ltd. — JPY 21 billion
4538 · Fuso Pharmaceutical Industries,Ltd. — JPY 19 billion
SYNCOMF · Syncom Formulations (India) Limited — ₹19 billion
0013 · HUTCHMED (China) Limited — HK$19 billion
HESTERBIO · Hester Biosciences Limited — ₹19 billion

← VENUSPIPES All “V” companies VEON →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.